Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-31

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

NCT06436040

Tumor Microenvironment Lung Squamous Cell Carcinoma Neoadjuvant Chemoimmunotherapy

RECRUITING

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

NCT04945200

Non-small Cell Lung Cancer

UNKNOWN

Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.

NCT05044728

Non-small Cell Lung Cancer Esophageal Squamous Cell Carcinoma

UNKNOWN PHASE2

The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

NCT06647836

Squamous Cell Lung Cancer

ENROLLING_BY_INVITATION

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

NCT06837948

Locally Advanced Non-Small Cell Lung Cancer

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer Stage ⅢA Non-small Cell Lung Cancer Stage IIIB

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chemoimmunotherapy group 1

patients received different cycles of neoadjuvant chemoimmunotherapy

cycles of neoadjuvant therapy and duration of waiting for surgery

Intervention Type OTHER

We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

chemoimmunotherapy group 2

the duration of before patients received surgery after neoadjuvant chemoimmunotherapy

cycles of neoadjuvant therapy and duration of waiting for surgery

Intervention Type OTHER

We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cycles of neoadjuvant therapy and duration of waiting for surgery

We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed as primary lung cancer through cytology or histological examination;

* ECOG score of 0 or 1; ③ 18 years old or above;

* Received imaging examination, with a preliminary clinical staging of stage III;

* Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available.

Exclusion Criteria

* Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders;

* Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No